Oxford Cannabinoid Technologies
  • Home
  • About
    • About Us
    • Executive Team
    • Board of Directors
    • Scientific Advisors
    • ESG
  • Our Science
    • Cannabinoid Medicine
    • Cannabinoids and Pain
    • Other Indications
    • Our Research Partners
  • Our Pipeline
    • Visual Pipeline
    • Programme 1 OCT461201
    • Programme 2 OCT130401
    • Programme 3 & 4
  • Investors
    • Chair's Welcome
    • Business Model & Strategy
    • Annual Report and Interim Results
    • Share Price Information
    • Regulatory News
    • Financial Calendar
    • Board of Directors
    • Investor Relations and Research Reports
    • Investor Q&A
    • Corporate Governance
    • Key Documents
  • News Centre
    • Press Releases
    • Articles & Podcasts
    • Media Contact
    • Press Pack
  • Contact
Oxford Cannabinoid Technologies
  • About
    • About Us
    • Executive Team
    • Board of Directors
    • Scientific Advisors
    • ESG
  • Our Science
    • Cannabinoid Medicine
    • Cannabinoids and Pain
    • Other Indications
    • Our Research Partners
  • Our Pipeline
    • Visual Pipeline
    • Programme 1 OCT461201
    • Programme 2 OCT130401
    • Programme 3 & 4
  • Investors
    • Chair's Welcome
    • Business Model & Strategy
    • Annual Report and Interim Results
    • Share Price Information
    • Regulatory News
    • Financial Calendar
    • Board of Directors
    • Investor Relations and Research Reports
    • Investor Q&A
    • Corporate Governance
    • Key Documents
  • News Centre
    • Press Releases
    • Articles & Podcasts
    • Media Contact
    • Press Pack
  • Contact
Skip Navigation LinksHome   >   News Centre   >   Press Pack

Press Pack 

Backgrounder - Cannabinoids and the Endocannabinoid System

Backgrounder - Company

OCTP Board of Directors

OCTP Management Team 

News Centre Press Releases Articles & Podcasts Media Contact Press Pack
News Centre Press Releases Articles & Podcasts Media Contact Press Pack

Cookies

We use cookies to ensure that we give you the best experience on our website. Find out more

Accept cookies

 

Privacy Policy   |   Terms of Use   

About

  • Team
  • Board
  • ESG

Research & Development

  • OCT461201
  • Cannabinoid Derivative Library
  • Pipeline
  • Research Partners and the OCT Science

Cannabinoids in Medicine

  • Pain
  • Other indications
  • References and Further Reading

Investors

  • Chairman's Welcome
  • Business Model & Strategy
  • Financial Results Centre
  • Share Price Information
  • Regulatory News
  • Financial Calendar
  • Board of Directors
  • Advisers
  • IR & Media Contacts
  • Corporate Governance
  • Key Documents

Media

Contact us

Oxford Cannabinoid Technologies.

Clarendon House
52 Cornmarket Street
Oxford
OX1 3HJ

Oxford Cannabinoid Technologies is a biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.

This website does not support your browser because it is out of date Update Browser